Olmutinib

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2016-2018
012320162018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
 
Is this relevant?
Review
2017
Review
2017
The identification of EGFR mutations and their respectively tyrosine kinase inhibitors (TKIs), changed dramatically treatment and… (More)
Is this relevant?
Review
2017
Review
2017
Discovery of sensitizing mutations in epidermal growth factor receptor (EGFR) and the subsequent development of EGFR tyrosine… (More)
Is this relevant?
Review
2017
Review
2017
The first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, and the… (More)
Is this relevant?
Review
2017
Review
2017
PURPOSE OF REVIEW The most common mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors… (More)
  • figure 1
Is this relevant?
2016
2016
Olmutinib (Olita(TM)) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is… (More)
Is this relevant?
Review
2016
Review
2016
The first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (1/2G EGFR-TKIs) gefitinib… (More)
  • table 1
Is this relevant?